121 related articles for article (PubMed ID: 38728186)
61. Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study.
Gao PY; Ou YN; Huang YM; Wang ZB; Fu Y; Ma YH; Li QY; Ma LY; Cui RP; Mi YC; Tan L; Yu JT
J Neurochem; 2024 Jan; 168(1):39-51. PubMed ID: 38055867
[TBL] [Abstract][Full Text] [Related]
62. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.
Hoscheidt SM; Starks EJ; Oh JM; Zetterberg H; Blennow K; Krause RA; Gleason CE; Puglielli L; Atwood CS; Carlsson CM; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016 Apr; 52(4):1373-83. PubMed ID: 27079723
[TBL] [Abstract][Full Text] [Related]
63. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
64. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
[TBL] [Abstract][Full Text] [Related]
65. Odor identification as a biomarker of preclinical AD in older adults at risk.
Lafaille-Magnan ME; Poirier J; Etienne P; Tremblay-Mercier J; Frenette J; Rosa-Neto P; Breitner JCS;
Neurology; 2017 Jul; 89(4):327-335. PubMed ID: 28659431
[TBL] [Abstract][Full Text] [Related]
66. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
67. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
Blennow K; Shaw LM; Stomrud E; Mattsson N; Toledo JB; Buck K; Wahl S; Eichenlaub U; Lifke V; Simon M; Trojanowski JQ; Hansson O
Sci Rep; 2019 Dec; 9(1):19024. PubMed ID: 31836810
[TBL] [Abstract][Full Text] [Related]
68. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
69. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.
Racine AM; Clark LR; Berman SE; Koscik RL; Mueller KD; Norton D; Nicholas CR; Blennow K; Zetterberg H; Jedynak B; Bilgel M; Carlsson CM; Christian BT; Asthana S; Johnson SC
J Alzheimers Dis; 2016 Oct; 54(4):1395-1408. PubMed ID: 27589532
[TBL] [Abstract][Full Text] [Related]
70. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
Geng C; Tan L; Chen C
Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
[TBL] [Abstract][Full Text] [Related]
71. Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer's disease pathology and cognitive function.
Zhao LJ; Wang ZT; Ma YH; Zhang W; Dong Q; Yu JT; Tan L;
BMC Neurol; 2021 Oct; 21(1):387. PubMed ID: 34615471
[TBL] [Abstract][Full Text] [Related]
72. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
73. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
74. Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
Babulal GM; Chen L; Murphy SA; Carr DB; Morris JC
Neurology; 2024 Jun; 102(12):e209426. PubMed ID: 38776513
[TBL] [Abstract][Full Text] [Related]
75. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
[TBL] [Abstract][Full Text] [Related]
76. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
[TBL] [Abstract][Full Text] [Related]
78. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
79. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
80. The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa.
Schwinne M; Alonso A; Roberts BR; Hickle S; Verberk IMW; Epenge E; Gikelekele G; Tsengele N; Kavugho I; Mampunza S; Yarasheski KE; Teunissen CE; Stringer A; Levey A; Ikanga J
J Alzheimers Dis; 2024; 97(3):1353-1363. PubMed ID: 38306056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
